Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 24, 2023 8:00 AM

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesSAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of...

Read more

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

May 24, 2023 8:00 AM

MINNEAPOLIS, MN / ACCESSWIRE / May 24, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences:One-on-one and small group meetings at the 20th Annual Craig-Hallum Institutional Investor Conference in Minneapolis on...

Read more

Adolore Biotherapeutics Enters into Exclusive License Agreement with University of Pittsburgh for Patents Protecting Non-Toxic Replication-Defective HSV Vectors for Efficient Gene Delivery Applications and Complementing Cells for Their Production

May 23, 2023 10:00 AM

Company developing next generation, disease-modifying, non-opioid analgesic gene therapies for the treatment of chronic painDELRAY BEACH, FL / ACCESSWIRE / May 23, 2023 / Adolore Biotherapeutics, Inc. ("Adolore" or the "Company") a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) gene therapy treatments for pain, today announced it has entered into an exclusive licensing agreement with the...

Read more

Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

May 23, 2023 9:05 AM

DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utilityKELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce additional findings from last year's human clinical study HYPER-H21-4 ("the Study") demonstrating significant reductions in several pro-inflammatory...

Read more

Biomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)

May 23, 2023 8:00 AM

SAN JOSE, CA / ACCESSWIRE / May 23, 2023 / Earlier today Biomed Industries, Inc. issued a letter to the Board of Directors of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX).The letter described a proposal to acquire all the company's common stock for $1.60 per share which represents an 80% premium on the average price of $0.88 over the past 10 days, in which one share of Neoleukin will be exchanged for $1.00 in cash plus $0.60, or 0.075 share of...

Read more

ByoPlanet and Merck Animal Health Announce Partnership with USEF

May 23, 2023 8:00 AM

New collaboration to protect the health of animals through innovations in environmental infection controlATHENS, GA / ACCESSWIRE / May 23, 2023 / ByoPlanet, a wholly owned subsidiary of Plandai Biotechnology, Inc. (OTC PINK: PLPL) and Merck Animal Health are proud to announce a groundbreaking partnership with The United States Equestrian Federation (USEF) to advance animal health through innovative products and technologies. "We are proud to...

Read more

BioInvent Strengthens Management with Appointment of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

May 23, 2023 2:50 AM

LUND, SWEDEN / ACCESSWIRE / May 23, 2023 / BioInvent International (STO:BINV)Experienced regulatory affairs leader who has worked on all stages of product developmentWill play important role in progress of pipeline of four assets in five clinical trialsLund, Sweden - May 23, 2023 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class...

Read more

Ondine Biomedical Inc. Announces Annual Report for the Year Ended 31 December 2022

May 23, 2023 2:02 AM

VANCOUVER, BC / ACCESSWIRE / May 23, 2023 / Ondine Biomedical (AIM:OBI) announces that its Annual Report for the year ended 31 December 2022 was posted on 23 May 2022 and is available on the Ondine website at: https://ondinebio.com/investors/reports-documentation/Ondine Biomedical Inc. Angelika Vance, Corporate Communications+001 (1) 604 838 2702 Singer Capital Markets (Nominated Adviser and Joint Broker) Aubrey Powell, Asha Chotai, Sam...

Read more

TISSIUM Raises €50M in Series D Funding to Finance its Commercial Launch and Platform Extension

May 23, 2023 12:45 AM

PARIS, FRANCE and BOSTON, MA / ACCESSWIRE / May 23, 2023 / TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and...

Read more

Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

May 22, 2023 8:00 AM

BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the presentation of preclinical data from the Company's inhaled Jagged-1 targeting program, PRS-400, at the annual American Thoracic Society (ATS) International...

Read more

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

May 21, 2023 8:00 AM

BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor (CTGF) antagonist program, PRS-220, for idiopathic pulmonary fibrosis...

Read more

Virogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science Review

May 19, 2023 8:30 AM

COLLEGE STATION, TX / ACCESSWIRE / May 19, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) Enzolytics wants to inform its shareholders that the ownership of the Company's patented technology is held exclusively in the name of The Zhabilov Trust, with Diana Zhabilov serving as the trustee of the trust. This ownership is verified by a review of the records filed with the USPTO and shown on the USPTO web site www.uspto.gov....

Read more

Plandai Subsidiary ByoPlanet Announces Strategic Distribution Agreement with Merck Animal Health

May 19, 2023 8:00 AM

ATHENS, GA / ACCESSWIRE / May 19, 2023 / ByoPlanet, a leading provider of advanced disinfection solutions and a wholly owned subsidiary of Plandai Biotechnology Inc. (the "Company") (OTC PINK:PLPL), is excited to announce the establishment of a comprehensive one-year distribution agreement with Merck Animal Health, a global leader in animal health solutions and a division of Merck & Co., to distribute Merck Animal Health's Armatrex...

Read more

Following Completed Share Exchange Agreement with ByoPlanet, Plandai Announces Material Rebranding to Disinfectant Industry Focus

May 18, 2023 11:00 AM

ATHENS, GA / ACCESSWIRE / May 18, 2023 / Plandai Biotechnology (OTC PINK:PLPL) is pleased to announce a comprehensive rebranding initiative following the successful completion of its share exchange agreement with ByoPlanet, LLC. Furthermore, Plandai is proud to state that all the contingencies required for closing have been satisfied, and as a result of the share exchange, all of ByoPlanet's assets have been rolled up into Plandai, thereby...

Read more

Fertilix Proven Effective in Blocking Damage From Low-Dose Exposure to Chemicals Commonly Found in Plastic Consumer Products

May 18, 2023 10:00 AM

CLERMONT-FERRAND, FRANCE / ACCESSWIRE / May 18, 2023 / According to a recent study by Université Clermont Auvergne researchers, exposure to chemical additives and building blocks commonly used in everyday plastic products, even in low doses, can cause significant damage to the genetic material carried by sperm cells.Fertilix® logo The study, led by Professor Joël Drevet, examined two common chemicals widely used in the plastic...

Read more

Biovica Signs the First Commercial Agreement for DiviTum(R) TKa in US

May 17, 2023 3:25 PM

UPPSALA, SE / ACCESSWIRE / May 17, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica today announces that Biovica Inc, the US laboratory and subsidiary of Biovica International AB, has signed a provider contract with MediNcrease Health Plans, a US, national provider network and provider advocacy firm, to make Biovica's blood test DiviTum® TKa available to the more than 15 million lives served by Clients and Payers...

Read more

ByoPlanet Announces Completion of Share Exchange Agreement with Plandai Biotechnology

May 17, 2023 9:15 AM

ATHENS, GA / ACCESSWIRE / May 17, 2023 / Plandai Biotechnology, Inc. (OTC PINK:PLPL), a Nevada corporation ("PLPL" or "Plandai"), GOOD SALT, LLC, a Florida limited liability company doing business as ByoPlanet ("ByoPlanet"), and the beneficial interest owners of ByoPlanet (together, the "Parties") announce today the completion of a share exchange agreement (the "Agreement") whereby PLPL shall acquire one hundred percent (100%) of the issued and...

Read more

Form Bio Selected by Google Cloud to Help Organizations Adopt New AI-Powered Life Sciences Solutions

May 17, 2023 9:00 AM

Google Cloud's Multiomics Suite Delivers Powerful AI and Bioinformatics Tools for Biotech Companies, Pharmaceutical Firms, and Public Sector OrganizationsDALLAS, TX / ACCESSWIRE / May 17, 2023 / Form Bio, the breakthrough computational life sciences platform, announced today that it has been selected to help organizations adopt Google Cloud's Multiomics Suite, accelerating the research of life science companies and academic institutions. In...

Read more

ASCO 2023 Spotlight: Claudin 6 Anticipated To Shine

May 17, 2023 9:00 AM

PHILADELPHIA, PA / ACCESSWIRE / May 17, 2023 / The escalating battle between Claudin 6 (CLDN6) immunotherapies from Amgen, BioNTech and Context Therapeutics, and CLDN6 antibody-drug-conjugates (ADC) from Daiichi-Sankyo and TORL BioTherapeutics will be a highlight of the upcoming 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023), taking place on June 2-6, 2023, in Chicago, IL. At ASCO 2023, BioNTech and TORL will present...

Read more

Announcement from Biovica International AB's Extra General Meeting

May 17, 2023 8:35 AM

UPPSALA, SE / ACCESSWIRE / May 17, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 17 May 2023 and the following resolutions were passed by the meeting.EMPLOYEE STOCK OPTION PROGRAM 2023/2026 FOR SENIOR EXECUTIVES, OTHER EMPLOYEES AND KEY INDIVIDUALS WITHIN THE COMPANY'S AMERICAN GROUPThe extra general meeting resolved, in...

Read more